Menarini Group and Insilico Medicine ink agreement for Novel KAT6 inhibitor for treatment of breast cancer
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
The deal includes upfront payments, milestone payments and ongoing royalties
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Global Ayurveda Festival organising in Thiruvananthapuram from 1st to 5th December
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Evinova will operate as a separate health-tech business within AstraZeneca
The company has raised US$4.5 million in funding for its AI operating system
Subscribe To Our Newsletter & Stay Updated